



Sarcoma SSCRG 18th January 2013

Sue Forsey







SACT

- Systemic Anti-Cancer Therapy Information Standard
- NHS Information Standard Board approval
- Implementation from April 2012- April 2014
- Covers all drug treatment for cancer in all settings
- 102 out of 154 trusts supplied and approved data to end December (67%)
- Database currently contains data on 63,124 patients

Number of hospital trusts submitting chemotherapy data, by month of activity

Note: There are **153** hospital trusts in England known by CIU to be delivering chemotherapy services **Source:** SACT dataset, accessed 8th January 2013






<u>Key</u>

Hospitals

- Submitting data
- Not submitting data

Number of patients

1 to 5 More than 5




London detail

SACT field structure

- Demographics and provider
- Clinical status
- Programme and regimen
- Cycle
- Drug details
- Outcome

[Date of death added from ONS]

Dataset structure



SACT mandatory fields

- NHS number
- Date of birth
- Patient postcode
- Organisation code of provider
- Primary diagnosis and/or Morphology
- Regimen
- Start date of regimen
- Cycle number


Data collection and analysis

- The Chemotherapy Intelligence Unit (CIU), is based at Oxford within the Cancer Registry
- Data are sent from trusts on a monthly basis and series of validation processes are applied
- A suite of routine analyses and reporting has been developed and 3 and 6-month reports issued
- Benchmarking has been tested in a limited number of tumour sites and is being evaluated

Optimising the upload

- Current OPCS regimens should be sent as 35 character Dataset short version.
- Regimens not in the above group, should be sent with the constituent drug approved name/s in alphabetical order.
- Trial regimens should be submitted with the full trial name.
- Bisphosphonates, hormones and other drugs which have a direct anti-cancer effect should also be submitted.

Results of Regimen Mapping Process



Source: SACT dataset; retrieved 8th January 2013


Analysis

Sarcoma ICD-10 diagnoses in SACT

| ICD-10 | Description | |
|--------|---|--|
| C40 | Bone and articular cartilage of limbs | |
| C41 | Bone and articular cartilage of other and unspecified | |
| C46 | Kaposi's sarcoma | |
| C48 | Retroperitoneum and peritoneum (also included in gynae) | |
| C49 | Other connective and soft tissue | |

Number of Patients by Diagnostic Group

All submitting trusts aggregated. Patients aged 16 and over. Data received for April – September 2012



Number of Patients by Diagnostic Group

All submitting trusts aggregated
Data received for April - August 2012. Patients aged 16 and over


| Primary Diagnosis | All submitting trusts aggregated |
|-------------------|----------------------------------|
| Breast | 11,058 |
| Lower GI | 6,866 |
| Lung | 5,403 |
| Urology | 4,610 |
| Lymphoma | 4,190 |
| Upper GI | 3,942 |
| Gynae | 3,732 |
| Myeloma | 1,899 |
| Leukaemia | 1,529 |
| Head and Neck | 816 |
| Brain/CNS | 756 |
| Sarcoma | 404 |
| Other | 2,646 |

Top Regimens by Diagnostic Group

Sarcoma

ICD10: C40-C41, C46, C49

All submitting trusts aggregated Data received for April - September 2012. Patients aged 16 and over



Top Regimens by Diagnostic Group

Sarcoma

ICD10: C40-C41, C46, C49

All submitting trusts aggregated

Data received for April - September 2012. Patients aged 16 and over

| Regimen | First Cycles | Total Cycles |
|-------------------------|--------------|--------------|
| DOXORUBICIN | 35 | 149 |
| TRABECTEDIN | 28 | 111 |
| MIFAMURTIDE | 3 | 99 |
| LIPOSOMAL DAUNORUBICIN | 15 | 92 |
| DOCETAXEL + GEMCITABINE | 24 | 90 |
| ABIRATERONE | 3 | 72 |
| CAPECITABINE | 1 | 72 |
| PACLITAXEL | 10 | 70 |
| EURO-EWING | 11 | 65 |
| DOCETAXEL | 9 | 64 |





www.chemodataset.nhs.uk

ciu@sph.nhs.uk

Helpdesk 01865 334 783



